MEDI-575, now known as the drug Tovetumab, represents a promising advancement in oncologic therapy , targeting selectively the receptor Ligand HGFR . Preliminary human trials suggest it showcases https://tovetumab-anti-pdgfr-ant901481.blognody.com/profile